bluebird bio, Inc.
TGFBeta SIGNAL CONVERTOR
Last updated:
Abstract:
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Status:
Application
Type:
Utility
Filling date:
17 Nov 2017
Issue date:
21 Nov 2019